First Expedited NGS Test Breaks Through FDA Review

FDA has approved FoundationOne CDx, the first next-generation sequencing test to clear the agency's expedited access pathway as a breakthrough-designated diagnostic. The companion diagnostic also nabbed a positive national Medicare coverage propose simultaneously thanks to the FDA/CMS Parallel Review Program.

Foundation Medicine Inc.'s FoundationOne CDx, a multi-drug companion diagnostic test, was approved by via US FDA's Breakthrough Device Program and gained a simultaneous national Medicare coverage policy proposal under the FDA/CMS' Parallel Review Program, making it the first in vitro diagnostic to successfully clear both programs simultaneously. It is also only the second device to reach this stage in the parallel-review process.

FoundationOne CDx, also known as F1CDx, is a next-generation sequencing IVD that can detect genetic mutations in 324 genes and...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Regulation

More from Policy & Regulation